Protagonist Therapeutics, Inc. (PTGX) Financial Statements

Executive TeamFinancials
Shareholders

Protagonist Therapeutics financial statements at a glance

Protagonist Therapeutics reported revenue of $46.02 million for fiscal year 2025 (ended December 31, 2025), down 89.4% from fiscal year 2024. Net income was -$130.15 million, a net margin of 282.8% loss, and diluted earnings per share were -$2.05.

At the end of fiscal year 2025 it had total assets of $668.19 million, total liabilities of $53.48 million and shareholders' equity of $614.71 million, with cash and short-term investments of $567.36 million and total debt of $10.32 million.

Its operations brought in $57.67 million of cash; capital spending was $1.59 million, leaving free cash flow of $56.08 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

PTGX logo

Protagonist Therapeutics, Inc.

PTGXUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
46.02M
Prev Year: 434.43M
YoY: -89.4%
Operating Revenue
46.02M
Prev Year: 434.43M
YoY: -89.4%
Operating Expense
204.14M
Prev Year: 181.59M
YoY: +12.4%
Selling General and Administrative
44.85M
Prev Year: 43.46M
YoY: +3.2%
General and Administrative Expense
44.85M
Prev Year: 43.46M
YoY: +3.2%
Other General and Administrative
44.85M
Prev Year: 43.46M
YoY: +3.2%
Research and Development
159.29M
Prev Year: 138.13M
YoY: +15.3%
Operating Income
-158.13M
Prev Year: 252.84M
YoY: -162.5%
Net Non Operating Interest Income Expense
28.79M
Prev Year: 26.32M
YoY: +9.4%
Non-operating Interest Income
28.79M
Prev Year: 26.32M
YoY: +9.4%
Other Income Expense
27.0K
Prev Year: 250.0K
YoY: -89.2%
Other Non-operating Income (expense)
27.0K
Prev Year: 250.0K
YoY: -89.2%
Special Income Charges
-
Gain on Sale of Securities
-
Pre-tax Income
-129.31M
Prev Year: 279.41M
YoY: -146.3%
Provision for Income Taxes
838.0K
Prev Year: 4.22M
YoY: -80.1%
Net Income Common Stockholders
-130.15M
Prev Year: 275.19M
YoY: -147.3%
Net Income
-130.15M
Prev Year: 275.19M
YoY: -147.3%
Net Income Including Non-Controlling Interests
-130.15M
Prev Year: 275.19M
YoY: -147.3%
Net Income from Continuing Operations
-130.15M
Prev Year: 275.19M
YoY: -147.3%
Basic EPS
-2.05
Prev Year: 4.47
YoY: -145.9%
Diluted EPS
-2.05
Prev Year: 4.23
YoY: -148.5%
Weighted Average Shares (basic)
63.57M
Prev Year: 61.57M
YoY: +3.3%
Weighted Average Shares (diluted)
63.57M
Prev Year: 65.08M
YoY: -2.3%
Net Income from Continuing and Discontinued Operation
-130.15M
Prev Year: 275.19M
YoY: -147.3%
Normalized Income
-130.15M
Prev Year: 275.19M
YoY: -147.3%
Interest Income
28.79M
Prev Year: 26.32M
YoY: +9.4%
Net Interest Income
28.79M
Prev Year: 26.32M
YoY: +9.4%
EBIT
-158.13M
Prev Year: 252.84M
YoY: -162.5%
EBITDA
-156.85M
Prev Year: 255.74M
YoY: -161.3%
Reconciled Depreciation
1.28M
Prev Year: 2.90M
YoY: -55.8%
Interest Expense
-
Net Income from Continuing Operation Net Minority Interest
-130.15M
Prev Year: 275.19M
YoY: -147.3%
Normalized EBITDA
-156.85M
Prev Year: 255.74M
YoY: -161.3%
Tax Rate for Calcs
0.21
Prev Year: 0
Total Expenses
204.14M
Prev Year: 181.59M
YoY: +12.4%
Total Operating Income as Reported
-158.13M
Prev Year: 252.84M
YoY: -162.5%
Total Unusual Items Excluding Goodwill
-
Diluted NI Available to Com Stockholders
-130.15M
Prev Year: 275.19M
YoY: -147.3%
Total Unusual Items
-
Values in USD

Protagonist Therapeutics key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$46.0M$434.4M$60.0M$26.6M$27.4M
Operating income-$158.1M$252.8M-$93.7M-$131.4M-$125.8M
Net income-$130.1M$275.2M-$79.0M-$127.4M-$125.6M
Diluted EPS-$2.05$4.23-$1.39-$2.60-$2.71
Total assets$668.2M$744.7M$358.0M$247.9M$347.7M
Total liabilities$53.5M$69.4M$21.3M$32.3M$47.7M
Shareholders' equity$614.7M$675.3M$336.7M$215.6M$300.0M
Cash and short-term investments$567.4M$418.9M$341.6M$237.4M$326.9M
Total debt$10.3M$10.9M$1.1M$3.7M$5.9M
Operating cash flow$57.7M$184.2M-$70.2M-$108.1M-$107.9M
Capital spending$1.6M$1.4M$609,000$795,000$1.1M
Free cash flow$56.1M$182.8M-$70.8M-$108.9M-$109.0M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Protagonist Therapeutics's revenue in fiscal year 2025?

$46.02 million, down 89.4% from $434.43 million in fiscal year 2024.

How much profit does Protagonist Therapeutics make?

Protagonist Therapeutics reported net income of -$130.15 million for fiscal year 2025 (282.8% of revenue); operating income was -$158.13 million.

How much cash and debt does Protagonist Therapeutics have?

At the end of fiscal year 2025: cash and short-term investments of $567.36 million and total debt of $10.32 million.

What is Protagonist Therapeutics's free cash flow?

$56.08 million in fiscal year 2025 (operating cash flow of $57.67 million minus capital spending of $1.59 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube